ABBV vs AZN
AbbVie Inc. and AstraZeneca PLC, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ABBV | AZN |
|---|---|---|
| Revenue | $61.2B | $58.7B |
| Net income | $4.2B | $10.2B |
| Gross margin | 70.2% | 81.9% |
| Net margin | 6.9% | 17.4% |
| Return on equity | · | 22.9% |
| Diluted EPS | $2.36 | $6.54 |
| Dividend / share | $6.65 | $3.13 |
| Payout ratio | 275.8% | 48.6% |
| Free cash flow | $17.8B | $11.8B |
| Equity | $-3.3B | $48.7B |
| Net debt / equity | · | 0.49× |
| Current ratio | 0.67× | 0.94× |
| Revenue CAGR 5y | 6.0% | 17.2% |
| Profit CAGR 5y | −1.7% | 26.2% |
ABBV and AZN book revenue within 15% of each other, and AZN keeps more of each dollar of revenue as profit (17.4% against 6.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ABBV | AZN |
|---|---|---|
| FY2025 | $61.2B | $58.7B |
| FY2024 | $56.3B | $54.1B |
| FY2023 | $54.3B | $45.8B |
| FY2022 | $58.1B | $44.4B |
| FY2021 | $56.2B | $37.4B |
| FY2020 | $45.8B | $26.6B |
| FY2019 | $33.3B | $24.4B |
| FY2018 | $32.8B | $22.1B |
| FY2017 | $28.2B | $22.5B |
| FY2016 | $25.6B | $23.0B |
Bottom line
| Fiscal year | ABBV | AZN |
|---|---|---|
| FY2025 | $4.2B | $10.2B |
| FY2024 | $4.3B | $7.0B |
| FY2023 | $4.9B | $6.0B |
| FY2022 | $11.8B | $3.3B |
| FY2021 | $11.5B | $112.0M |
| FY2020 | $4.6B | $3.2B |
| FY2019 | $7.9B | $1.3B |
| FY2018 | $5.7B | $2.2B |
| FY2017 | $5.3B | $3.0B |
| FY2016 | $6.0B | $3.5B |
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$2,421,000,000 | ABBV |
| FY2024 | +$2,261,000,000 | ABBV |
| FY2023 | +$8,507,000,000 | ABBV |
| FY2022 | +$13,703,000,000 | ABBV |
| FY2021 | +$18,780,000,000 | ABBV |
| FY2020 | +$19,187,000,000 | ABBV |
| FY2019 | +$8,882,000,000 | ABBV |
| FY2018 | +$10,663,000,000 | ABBV |
| FY2017 | +$5,751,000,000 | ABBV |
| FY2016 | +$2,636,000,000 | ABBV |
| FY2015 | −$1,849,000,000 | AZN |
The higher-revenue side has changed between ABBV and AZN over this period. The gap has widened since the earliest year compared.
11 of 15 comparable fiscal years — a year missing data on either side is not counted.
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −10.5 pp | AZN |
| FY2024 | −5.4 pp | AZN |
| FY2023 | −4.0 pp | AZN |
| FY2022 | +13.0 pp | ABBV |
| FY2021 | +20.2 pp | ABBV |
| FY2020 | −1.7 pp | AZN |
| FY2019 | +18.7 pp | ABBV |
| FY2018 | +8.1 pp | ABBV |
| FY2017 | +6.0 pp | ABBV |
| FY2016 | +8.4 pp | ABBV |
| FY2015 | +11.1 pp | ABBV |
The higher net margin has changed hands between ABBV and AZN over this period.
11 of 12 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ABBV's net margin has been more volatile than AZN's over the 11 comparable fiscal years — 6.3 percentage points of standard deviation against 4.6.
11 of 12 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ABBV and AZN over these 11 fiscal years — ABBV led in 7 and AZN in 4.
11 of 12 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ABBV's return on equity has been more volatile than AZN's over the 7 comparable fiscal years — 46.0 percentage points of standard deviation against 6.7.
7 of 12 comparable fiscal years — a year missing data on either side is not counted.
Year by year
ABBV led in return on equity in every one of the 7 comparable fiscal years — a structural lead, not a recent swing.
7 of 12 comparable fiscal years — a year missing data on either side is not counted.